Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2025PathogensOpen Access

Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMaria KourtiPEPaschalis EvangelidisEREmmanuel Roilides

Discussion

Loading...

Member takes

Overview

Literature review highlights CAR immunotherapy's potential impact on chronic infections in immunocompromised patients, suggesting novel treatment avenues.

Key Points

  • Chimeric antigen receptor (CAR) immunotherapy shows promise in treating chronic infections in immunocompromised patients.
  • Emerging evidence supports using CAR-engineered cells beyond T cells for addressing multidrug-resistant pathogens.
  • Current clinical studies focus on CAR immunotherapy for human immunodeficiency virus, while other data derive from preclinical models.
  • The need for personalized and effective therapies for managing infectious complications underscores the importance of ongoing research.

Cite This Study

Kourti et al. (2025) studied this question.

synapsesocial.com/papers/689522009f4f1c896c428ea2https://doi.org/10.3390/pathogens14080774
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer2025 · 10 citations
  2. 2CAR-based cell therapy for autoimmune diseases2025 · 6 citations
  3. 3Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases2025
  4. 4Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic Impact2025
  5. 5Innate Immune Cells in Chimeric Antigen Receptor Therapy2025 · 6 citations